Evidence map›Paper›PMID 34963683›Full record

ArticleScientific reports2021

Potential of [

Emmi Puuvuori, Johanna Rokka, Per-Ola Carlsson, Zhanchun Li, Jonas Eriksson, Olof Eriksson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Imaging Synaptic Vesicle Protein SV2C withACS chemical neuroscience · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Emmi PuuvuoriScience for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Dag Hammarskjöldsv 14C, 3rd floor, 75183, Uppsala, Sweden. emmi.puuvuori@ilk.uu.se.
Johanna RokkaDepartment of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Per-Ola CarlssonDepartment of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
Zhanchun LiDepartment of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
Jonas ErikssonScience for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Dag Hammarskjöldsv 14C, 3rd floor, 75183, Uppsala, Sweden.
Olof ErikssonScience for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Dag Hammarskjöldsv 14C, 3rd floor, 75183, Uppsala, Sweden. olof.eriksson@ilk.uu.se.
Uppsala University · SEScience for Life Laboratory · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomarkers for the measurement of islets of Langerhans could help elucidate the etiology of diabetes. Synaptic vesicle glycoprotein 2 A (SV2A) is a potential marker reported to be localized in the endocrine pancreas. [

Indexed as

Positron-Emission TomographyAnimalsFemaleIslets of LangerhansMaleMembrane GlycoproteinsNerve Tissue ProteinsPositron Emission Tomography Computed TomographyPyridinesPyrrolidinonesRadiopharmaceuticalsRatsRats, Sprague-DawleySwine1-((3-(methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-oneMembrane GlycoproteinsNerve Tissue ProteinsPyridinesPyrrolidinonesRadiopharmaceuticalsSv2a protein, rat

Identifiers

PMID34963683
PMCPMC8714818
OpenAlexW4200374975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.